Instituto Oftalmologico Gomez-Ulla S.L.
- Address
- lock Available on a paid plan
Eye Diseases and Retinal Degeneration Research
At Instituto Oftalmologico Gomez-Ulla S.L., clinical research in ophthalmology focuses on eye diseases linked to progressive vision loss, especially geographic atrophy associated with age-related macular degeneration. These studies are designed to better understand long-term treatment safety and to explore whether new therapies can help slow disease progression and protect remaining vision.
- Long-term safety of treatments for geographic atrophy
- Evaluation of new options for age-related macular degeneration
- Assessment of treatment effects on retinal lesion growth
Overall, this work reflects a strong interest in improving care for chronic retinal conditions through therapies aimed at preserving vision and supporting patients over time.
Allergic Eye Disease and Symptom Relief Studies
Another key area at this hospital/clinic is research on atopic keratoconjunctivitis, a painful and persistent allergic condition affecting the eyes. The trials in this area are focused on testing whether new eye treatments can reduce ocular itching and improve day-to-day comfort for adults living with this condition.
- Testing new therapy for atopic keratoconjunctivitis
- Improving relief of ocular itching
- Evaluating symptom control in allergic eye disease
This research highlights a practical goal: finding safer and more effective ways to ease symptoms that can significantly affect quality of life.
Clinical Research on Long-Term Treatment Performance
The site also contributes to studies that follow patients over time to understand how well emerging ophthalmic therapies continue to perform after initial treatment. In particular, the research includes work on treatments for geographic atrophy secondary to age-related macular degeneration, with attention to safety, durability, and possible benefit in slowing retinal damage.
- Long-term safety evaluation of ophthalmic treatments
- Monitoring disease progression in geographic atrophy
- Studying sustained benefit in retinal disease
These trials support a broader effort to improve treatment strategies for patients with chronic, sight-threatening conditions.
Site Overview
Activity Indicator
Last 6 months
Trial Flow
How this site's trials are distributed across therapeutic areas and active substances (IMPs), and how they're positioned within their overall lifecycle status. Flow thickness represents the number of unique trials.
Compounds & Molecules Timeline
The time span of clinical-trial activity for the main active substances (IMPs) studied at this site over the last 8 years. Each bar runs from the earliest trial start to the most recent end; a substance with a trial still open has no recorded end and is shown as ongoing.
Sponsor & Partnership
Top sponsors by active trials, and the ones that have come back for more than one study.
Sponsor Network
Top 4 by active trials.
- 1Eyebiotech Limited1active
lock +3 more on a paid plan
Partnership History
Sponsors with repeated collaboration (≥ 2 trials).
- 1Eyebiotech Limited3trials
Sponsor Network Graph
How sponsors and therapeutic areas connect across this site's active trials: each link is at least one active trial shared between them, and bigger nodes mean more activity. Click a node to see its exact connections.
Country Benchmark
Compared to 567 other sites in Spain
Therapeutic Area Benchmark — Spain
Select a therapeutic area to compare against other sites in Spain.
Competitor Comparison
Similar sites in the same country running a comparable number of trials (within ±30%), scored on how closely their trial portfolios match this one. Higher percentages mean a more similar profile.
Country: Spain
Market Share
Country: Spain
Therapeutic Area Market Share
Select a therapeutic area to view its disease coverage breakdown.
Heat Maps & Advanced Analytics
How often specific conditions appear in trials across this site and comparable sites from the same country. Each row is a site, each column a condition, and each cell the number of trials on it — darker means more activity.
Other Trials in Instituto Oftalmologico Gomez-Ulla S.L.
lock Showing 1 of 9 trials — the rest is available on a paid plan.
| Trial | Sponsor | Phase | Status | Start Date | End Date |
|---|---|---|---|---|---|
| (22153) Randomized, Double-Masked, Active-Controlled, Phase 3 Study of the Efficacy and Safety of Aflibercept 8 mg in Macular Edema Secondary to Retinal Vein Occlusion | Bayer AG | Phase III | Not Recruiting | Sep 2023 | May 2025 |
IMP list
lock Showing 1 of 9 compounds — the rest is available on a paid plan.
| IMP | Trials | Status | First start | Last start |
|---|---|---|---|---|
| Fluorescein Sodium | 5 | Unknown | 2022-12-21 | 2026-06-22 |
Upgrade this site to Business Plan
Own the profile, publish your feasibility data and reach sponsors directly.
Is something out of date?
Tell us what needs correcting and we'll update this profile.
lock Available to Business plan sites only.